Navigation Links
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
Date:3/12/2009

ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien(TM). Iluvien is an intravitreal insert being developed for the treatment of diabetic macular edema (DME).

This 36-month, open-label, Phase 2 study, running concurrently with the pivotal Phase 3 FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), is designed primarily to assess systemic exposure of the corticosteroid, fluocinolone acetonide (FA), after administration of Iluvien in patients with DME. Secondarily, the PK Study is designed to provide information on the safety and efficacy of Iluvien in a DME patient population. A total of 37 subjects were enrolled in the PK Study, 20 patients on the low dose of Iluvien (an approximate 0.23 micrograms per day dose), and 17 patients on the high dose of Iluvien (an approximate 0.45 micrograms per day dose).

In the 12-month interim readout, no adverse events related to intraocular pressure (IOP) were seen in low dose patients, and 23.5 percent of the high dose patients experienced IOP increases of 30 millimeters of mercury (mmHg) or greater at some time point. By way of comparison, in published results from clinical studies of DME patients using sustained release intravitreal FA in Bausch & Lomb Incorporated's product Retisert(R), a surgically implanted intravitreal drug delivery device containing 0.59 mg FA approved for the treatment of chronic non-infectious posterior uveitis, 35 percent of the patients experienced IOP increases of 30 mmHg or greater at some time point during the first year.

"This profile of IOP changes occurring only in the high dose group is consistent with the IOP change profiles that
'/>"/>

SOURCE Alimera Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
2. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
3. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
7. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Vittamed Corporation , a neurodiagnostics medical ... today that T. (Teo) Forcht Dagi , MD, DmedSc, ... of Directors. " Teo Forcht Dagi ... medical innovation and venture capital," said Remis Bistras , ... add his clinical, strategic, and entrepreneurial expertise to our Board." ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)... Pixcelldata, the innovative Irish developer of digital ... new deal with Dutch based eX-Path, global providers of ... Marius Nap . The announcement was made ... which is taking placing between August 30th and September ... where Pixcelldata will demonstrate its innovative solution. ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... , HOFFMAN ESTATES, Ill., Sept. 30 Life Spine ... (FDA) has given 510(k) marketing approval to the SENTINEL ... provides rigid stabilization and promotes fusion from the occiput ... to address complicated procedures. Polyaxial screws are available in ...
... JERUSALEM, Israel, September 30 ... carlecortemcel-l, the generic,name of what is widely known as ... and lymphoma. The article, carlecortemcel-l, an ex vivo expanded,umbilical ... Ka Wah Chan and Dr. Demetrios Petropoulos, will be ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... patients who do not respond to traditional therapy can ... transplant, according to an Indiana University School of Medicine ... England Journal of Medicine. , About 90 percent ... involves multiple courses of cisplatin, first used successfully in ...
... are urgently needed to reduce climate-altering carbon emissions that ... the World Health Organisation said Monday. ,Climate change ... in the region, according to WHO estimates. ,"So ... If the trend continues, it may have an impact on ...
... for tougher regulations on tobacco, as officials from 145 ... global efforts to stop smoking. ,The ... aims to find ways of harmonising national laws to ... from second-hand smoke. ,Hatai Chitanondh, the president ...
... who have difficulty recognizing familiar smells could be experiencing an ... Monday. ,Scientists already know that the first ... in an area of the brain that is home to ... Center in Chicago tested 589 people aged between 54 to ...
... Idaho in US had a miraculous escape while traveling by an ... the pilot last Wednesday from Twin Falls, Idaho, to Seattle when ... at a height of 20,000 ft. ,Rapid decompression occurred ... water bottle. Fogg's head and right arm were pulled outside the ...
... New York based Columbia University Medical Center has shown that ... form of alcohol use disorder at some point in ... the adults surveyed reported experiencing alcohol abuse, and 12.5 per ... an article published in the Archives of General Psychiatry, one ...
Cached Medicine News:Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2Health News:Nurse Has Miraculous Escape as Window is Blown Off an Air Ambulance 2Health News:One-third of Adults Have Had Some Form of Alcohol Use Disorder During Their Lifetimes 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
... Nebulizer Small Volume Medication Mouthpiece 7FT O 2 ... ,An advanced jet design for fast treatment times ... with a tighter distribution (higher percentage of respirable ... ,Our AirLife™ brand Misty Max 10™ disposable nebulizers ...
Medicine Products: